Jeff Yass’s Ascendis Pharma A/S ASND Stock Holding History

Jeff Yass’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324K	Sell	1,215 -26,847	-96%	-$6.27M	﹤0.01%	10874
2026 Q1	$6.42M	Sell	28,062 -442,889	-94%	-$99.3M	﹤0.01%	3824
2025 Q4	$100M	Buy	+470,951	New	+$97.3M	0.01%	887
2025 Q2	–	Sell	-11,395	Closed	-$1.86M	–	12608
2025 Q1	$1.78M	Sell	11,395 -18,465	-62%	-$2.64M	﹤0.01%	5788
2024 Q4	$4.11M	Buy	29,860 +27,854	+1,389%	+$3.66M	﹤0.01%	3903
2024 Q3	$300K	Sell	2,006 -4,307	-68%	-$582K	﹤0.01%	9609
2024 Q2	$861K	Buy	+6,313	New	+$859K	﹤0.01%	6936
2023 Q4	–	Sell	-19,330	Closed	-$1.93M	–	12304
2023 Q3	$1.81M	Buy	19,330 +4,696	+32%	+$439K	﹤0.01%	5325
2023 Q2	$1.31M	Buy	+14,634	New	+$1.27M	﹤0.01%	6071
2023 Q1	–	Sell	-7,081	Closed	-$810K	–	12523
2022 Q4	$865K	Sell	7,081 -38,381	-84%	-$4.46M	﹤0.01%	6503
2022 Q3	$4.69M	Buy	+45,462	New	+$4.31M	﹤0.01%	3265
2022 Q2	–	Sell	-36,587	Closed	-$3.45M	–	12825
2022 Q1	$4.29M	Buy	36,587 +10,092	+38%	+$1.17M	﹤0.01%	3904
2021 Q4	$3.56M	Buy	26,495 +19,920	+303%	+$2.96M	﹤0.01%	4348
2021 Q3	$1.05M	Sell	6,575 -15,043	-70%	-$2.06M	﹤0.01%	7433
2021 Q2	$2.84M	Buy	21,618 +12,592	+140%	+$1.68M	﹤0.01%	5144
2021 Q1	$1.16M	Sell	9,026 -7,508	-45%	-$1.14M	﹤0.01%	7320
2020 Q4	$2.76M	Sell	16,534 -5,373	-25%	-$889K	﹤0.01%	4450
2020 Q3	$3.38M	Buy	21,907 +18,520	+547%	+$2.66M	﹤0.01%	3664
2020 Q2	$501K	Buy	3,387 +199	+6%	+$27.3K	﹤0.01%	7353
2020 Q1	$359K	Sell	3,188 -174,973	-98%	-$22.7M	﹤0.01%	7631
2019 Q4	$24.8M	Sell	178,161 -4,562	-2%	-$507K	0.01%	1241
2019 Q3	$17.6M	Buy	182,723 +108,876	+147%	+$12.1M	0.01%	1441
2019 Q2	$8.5M	Buy	+73,847	New	+$8.84M	﹤0.01%	2057
2018 Q4	–	Sell	-132,442	Closed	-$8.32M	–	8892
2018 Q3	$9.38M	Sell	132,442 -85,103	-39%	-$5.86M	﹤0.01%	2004
2018 Q2	$14.5M	Buy	+217,545	New	+$14.3M	0.01%	1587

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Jeff Yass's ASND Position: Q2 2026 in Review

Jeff Yass reduced its Ascendis Pharma A/S (ASND) stake by 96% in Q2 2026, selling an estimated $6.27M and leaving 1,215 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #10874.

Jeff Yass first reported a position in ASND in Q2 2018 and has held it in 25 quarters since. The position peaked at $100M in Q4 2025. 310 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Jeff Yass held 1,215 shares of Ascendis Pharma A/S worth $324K as of Q2 2026.
Jeff Yass sold 26,847 Ascendis Pharma A/S shares in Q2 2026, an estimated $6.27M.
Ascendis Pharma A/S made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10874 holding.
Jeff Yass first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 25 quarters since.
Jeff Yass's Ascendis Pharma A/S position peaked at $100M in Q4 2025.
310 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.